John O'Gorman

John O'Gorman is a Senior Director of Biostatistics at Biogen, where they focus on late-stage Alzheimer's Disease compounds. With extensive experience in the biotechnology and pharmaceutical industry, John has successfully managed biostatistics for multiple Phase 1, 2, and 3 studies across various therapeutic areas, including progressive supranuclear palsy and multiple sclerosis. Their regulatory expertise includes interactions with FDA, EMA, and Health Canada, supporting initiatives that enhance operational efficiency. John holds a Ph.D. in Statistics from Penn State University and has previously held significant roles at Eli Lilly and Company and Biogen.